比较低剂量与标准剂量阿替普酶在血管内取栓中的效果:来自全国登记研究的启示
本研究基于台湾取栓登记研究,纳入2019年1月至2023年4月接受溶栓联合取栓的连续患者,比较低剂量(0.6 mg/kg)与标准剂量(0.9 mg/kg)阿替普酶的效果。结果显示标准剂量组成功再灌注率较低(81% vs 87%)、症状性颅内出血发生率数值较高(6.7% vs 3.9%),但90天功能独立率更高(47% vs 31%),90天死亡率数值较低(9% vs 15%)。
要点
- 标准剂量阿替普酶与较低成功再灌注率相关(81% vs 87%;aOR 0.63)。
- 标准剂量组90天功能独立率更高(47% vs 31%;aOR 1.91)。
- 症状性颅内出血和死亡率两组间无统计学显著差异。
核心结论
- 尽管标准剂量阿替普酶成功再灌注率较低且症状性颅内出血风险较高,但标准剂量与更好的功能结局相关。
研究设计与样本
- 多中心台湾急性缺血性卒中血管内取栓登记研究,纳入2019年1月至2023年4月接受联合溶栓(发病4.5小时内)和取栓治疗的连续患者。
- 共2242例患者中734例(33%)接受静脉阿替普酶,低剂量组360例,标准剂量组374例;剂量选择由医师决定。
主要发现
- 标准剂量组较低于低剂量组成功再灌注率(81% vs 87%;aOR 0.63 [95% CI, 0.40-0.98])。
- 标准剂量组症状性颅内出血发生率数值高于低剂量组(6.7% vs 3.9%;aOR 1.81 [95% CI, 0.88-3.69])。
- 标准剂量组90天功能独立(mRS 0-2)率高于低剂量组(47% vs 31%;aOR 1.91 [95% CI, 1.28-2.86])。
- 标准剂量组90天死亡率数值低于低剂量组(9% vs 15%;aOR 0.73 [95% CI, 0.43-1.25])。
关键数值与推荐
- 低剂量阿替普酶为0.6 mg/kg,标准剂量为0.9 mg/kg。
- 成功再灌注定义为改良脑梗死溶栓评分2b-3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Timely intravenous thrombolysis and endovascular thrombectomy are the standard reperfusion treatments for large vessel occlusion stroke. Currently, it is unknown whether a low-dose thrombolytic agent (0.6 mg/kg alteplase) can offer similar efficacy to the standard dose (0.9 mg/kg alteplase). METHODS: We enrolled consecutive patients in the multicenter Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke who had received combined thrombolysis (within 4.5 hours of onset) and thrombectomy treatment from January 2019 to April 2023. The choice of low- or standard-dose alteplase was based on the physician's discretion. The outcomes included successful reperfusion (modified Thrombolysis in Cerebral Infarction score, 2b-3), symptomatic intracerebral hemorrhage, 90-day modified Rankin Scale score, and 90-day mortality. The outcomes between the 2 groups were compared using multivariable logistic regression and inverse probability of treatment weighting-adjusted analysis. RESULTS: Among the 2242 patients in the Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke, 734 (33%) received intravenous alteplase. Patients in the low-dose group (n=360) were older, had more women, more atrial fibrillation, and longer onset-to-needle time compared with the standard-dose group (n=374). In comparison to low-dose alteplase, standard-dose alteplase was associated with a lower rate of successful reperfusion (81% versus 87%; adjusted odds ratio, 0.63 [95% CI, 0.40-0.98]), a numerically higher incidence of symptomatic intracerebral hemorrhage (6.7% versus 3.9%; adjusted odds ratio, 1.81 [95% CI, 0.88-3.69]), but better 90-day modified Rankin Scale score (functional independence [modified Rankin Scale score, 0-2], 47% versus 31%; adjusted odds ratio, 1.91 [95% CI, 1.28-2.86]), and a numerically lower mortality rate (9% versus 15%; adjusted odds ratio, 0.73 [95% CI, 0.43-1.25]) after adjusting for covariates. Similar results were observed in the inverse probability of treatment weighting-adjusted models. The results were consistent across predefined subgroups and age strata. CONCLUSIONS: Despite the lower rate of successful reperfusion and higher risk of symptomatic intracerebral hemorrhage with standard-dose alteplase, standard-dose alteplase was associated with a better functional outcome in patients receiving combined thrombolysis and thrombectomy.
引用
- Chen CH, Lee CW, Hsieh YC, et al. Comparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry. Stroke. 2024. PMID: 38314590. doi:10.1161/STROKEAHA.123.045851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。